Study #2024-0099
Phase II study of REPotrectinib with or without fulvestrant in patients with hormone receptor-positive human epidermal growth factor 2-negative metastatic invasive LObular carcinoma who received a prior endocrine Therapy in combination with cyclindependent kinase 4 and 6 inhibitor (REPLOT Trial)
MD Anderson Study Status
Enrolling
Treatment Agent
Fulvestrant, Repotrectinib
Description
To find out if the combination of repotrectinib and fulvestrant can control the disease in participants with metastatic invasive lobular carcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Study phase:
Phase II
Physician name:
Jason Mouabbi
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.